Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adverum Biotechnologies Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ADVM
Nasdaq
8731
https://adverum.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adverum Biotechnologies Inc
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Jan 18th, 2023 9:05 pm
Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
- Nov 10th, 2022 9:05 pm
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
- Nov 4th, 2022 4:08 pm
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
- Oct 27th, 2022 8:05 pm
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
- Sep 30th, 2022 8:45 pm
Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference
- Sep 27th, 2022 8:05 pm
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
- Sep 23rd, 2022 8:05 pm
Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation
- Sep 23rd, 2022 3:06 pm
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
- Sep 23rd, 2022 12:00 pm
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
- Sep 15th, 2022 9:19 pm
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration
- Sep 14th, 2022 12:00 pm
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- Sep 8th, 2022 8:05 pm
Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
- Aug 26th, 2022 8:05 pm
Adverum Biotechnologies Reports Second Quarter 2022 Financial Results
- Aug 11th, 2022 8:05 pm
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference
- Aug 10th, 2022 8:05 pm
Quite a few insiders invested in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) last year which is positive news for shareholders
- Jul 25th, 2022 11:16 am
Adverum Posts New Data From Wet AMD Gene Therapy Trial
- Jul 15th, 2022 1:52 pm
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
- Jul 15th, 2022 12:32 pm
Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022
- Jul 8th, 2022 12:00 pm
Adverum (ADVM) Completes IND Amendment for Gene Therapy Study
- Jul 7th, 2022 3:22 pm
Scroll